Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. - Wikidata - awgldk - TriplyDB

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

http://www.wikidata.org/entity/Q35659208

about

Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.Pretargeted radioimmunotherapy for hematologic and other malignancies Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.Radiolabeled nano-peptides show specificity for an animal model of human PC3 prostate cancer cells.A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery.Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.A semiempirical model of tumor pretargeting.The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size.Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.Use of Morpholino Oligomers for Pretargeting.

P2860

Q33661948-F2C26FBD-854D-4EB8-B697-6B77F95D2145 Q34113941-23CD9485-B52F-4CAA-899D-ECB7988D71F2 Q34126851-CC38953B-A3D1-4322-A4BF-49E45B60F57B Q34519414-546D221D-7C55-4D79-9F99-B3EAA3AB59BE Q34691475-84A9C19B-7054-4506-AF05-AF0F0069AB88 Q34979175-2607ECEC-CE0A-41EA-A3A1-D01E80F9A52E Q35629379-39E745DC-229F-4A14-97D0-E8B2E4EFA1D4 Q37154201-A0AB283C-D2F4-4384-8282-F238C0544B73 Q37233043-F7BBDB79-4433-471A-8BA7-7EAC152375F7 Q37288100-6230C63B-1080-4E0E-A93E-0E53B721CC92 Q37288717-D4FD4734-1F27-42CF-8F85-D4184605E458 Q37481714-E15FBD02-BAE4-4B3D-8E96-7C0475BDA971 Q38297700-792DA2D7-171C-4F59-9A12-EAD84C33E83E Q50665399-B64F0923-3469-4DCC-AB72-045DA8AA4B9D

P2860

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

http://www.wikidata.org/entity/Q35659208

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

@ast

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

@en

type

label

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

@ast

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

@en

prefLabel

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

@ast

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

@en

P1433

Q35659208-5823205B-025D-4575-90B9-DC472096ADAA

P1476

Q35659208-5A95BF13-D2D7-427B-8847-315B89963CC9

P2093

Q35659208-265E47CF-BF4C-4BF0-B523-DA0595B1D1C1

Q35659208-33DA5F7F-E771-4F06-8EC8-D71B400869DC

Q35659208-4917CF1E-A9A5-423A-9D65-1F57048D6A6D

Q35659208-5254BA16-E50B-46EE-A46D-2E1B7402BE13

Q35659208-536BEFF3-BA82-48F7-A3B6-D5D9D6067CF5

Q35659208-AD790241-F481-4181-83BD-46854B7D03FA

P2860

Q35659208-0D978793-D928-4024-BA74-F164D842D8EF

Q35659208-12747FA9-89E1-4FD0-AE37-E92181AAECAE

Q35659208-1776A328-67C3-46C7-A967-4C1EB8D21FA1

Q35659208-2F934E61-21D8-4428-86AE-102D184A2D88

Q35659208-4A902945-54A3-4A5C-99AF-03C934E97599

Q35659208-985D7437-6056-4882-B320-DD4F597CEC8A

Q35659208-B0203597-35CE-4ED8-AA3A-7176EE33642F

Q35659208-E429F871-FE53-45B9-9D0B-A82BE4C80488

Q35659208-E826FD35-E12A-41D2-8F62-AC0A3CF8E488

Q35659208-F4293171-D0FA-4D24-9E34-717120FCCC8E

P2888

Q35659208-9E3E0261-16E5-4D95-9B92-21671224C28C

P304

Q35659208-6DFDEAFA-BBC7-4554-9A78-B25A7806FF2D

P31

Q35659208-3BE85060-847C-43E9-AC82-CDFD5565EACC

P356

Q35659208-184B6626-6055-4CE8-8BEA-CD76F731A1BD

P433

Q35659208-F309CBEF-65D5-4CC4-B401-8F6B3D3216F2

P478

Q35659208-44D4D2C4-7849-4EC2-93BA-AEA813C39651

P577

Q35659208-49B1C470-71E4-4872-A62B-24CDBC3147EF

P5875

Q35659208-FACA784B-AC7B-40DC-A82C-2BC5729869B3

P698

Q35659208-3DD0446C-57C3-45CD-AF6A-41B9D25AB914

P932

Q35659208-490A77BD-7E96-4DF5-B408-C9D34D5A455A

P356

S00259-006-0222-3

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

@en

P2093

Donald J Hnatowich

http://www.w3.org/2001/XMLSchema#string

Guozheng Liu

http://www.w3.org/2001/XMLSchema#string

Jiang He

http://www.w3.org/2001/XMLSchema#string

Mary Rusckowski

http://www.w3.org/2001/XMLSchema#string

Shuping Dou

http://www.w3.org/2001/XMLSchema#string

Xinrong Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting.

Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor

An improved method for covalently conjugating morpholino oligomers to antitumor antibodies

Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA.

Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer.

Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.

Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.

Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

Cytosine residues influence kidney accumulations of 99mTc-labeled morpholino oligomers.

Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies.

P2888

s00259-006-0222-3

P304

237-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-006-0222-3

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6772855

http://www.w3.org/2001/XMLSchema#string

P698

17021815

http://www.w3.org/2001/XMLSchema#string

P932

1808331

http://www.w3.org/2001/XMLSchema#string